Thoracentesis: Symptoms and Prediction of the Need for Therapeutic Thoracentesis

Sponsor
Naestved Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04236934
Collaborator
(none)
107
2
26.7
53.5
2

Study Details

Study Description

Brief Summary

Recurrent fluid surrounding the lungs is associated with poor quality of life, the main symptom being dyspnea. These patients are in need of recurrent removal of the fluid using drainage. The mechanism causing dyspnea is not fully understood.

By using ultrasound to evaluate the movement of the diaphragm before and after removal of fluid and the patients symptoms before removal of fluid and until next removal the research group aims to clarify the temporal development in symptoms and the role of the diaphragm.

The researchers will also evaluate the ability of the pulmonologist and patient to predict when the patient will need the next removal of fluid in patients with recurrent unilateral pleural effusion.

Condition or Disease Intervention/Treatment Phase
  • Other: Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis

Detailed Description

Recurrent pleural effusion (PE) is associated with impaired quality of life, the main symptom being dyspnea. The mechanisms causing dyspnea in PE is not fully understood. These patients are in need of recurrent therapeutic thoracentesis.

By evaluating the movement of diaphragma before and after thoracentesis and measure the patients symptoms before thoracentesis and until the next thoracentesis the researchers aim to clarify the temporal development in symptoms and the role of the diaphragm.

The researchers will also evaluate the ability of the pulmonologist and patient to predict when the patient will need the next therapeutic thoracentesis in patients with recurrent unilateral pleural effusion.

Study Design

Study Type:
Observational
Actual Enrollment :
107 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Thoracentesis: Symptoms and Prediction of the Need for Therapeutic Thoracentesis: A Prospective Observational Study
Actual Study Start Date :
Jan 13, 2020
Actual Primary Completion Date :
Dec 31, 2021
Actual Study Completion Date :
Apr 4, 2022

Arms and Interventions

Arm Intervention/Treatment
All included patients

Patients with recurrent unilateral pleural effusion

Other: Assesment of diaphragm shape and diaphragm movement (by M-mode and the AREA-method) by ultrasound before and after thoracentesis
Questionnaire is about symptoms measured by Edmonton Symptom Assessment Score (ESAS) and dyspnea also by modified Borg Scale (MBS)
Other Names:
  • A questionnaire before and after thoracentesis and daily until next therapeutic thoracentesis
  • Outcome Measures

    Primary Outcome Measures

    1. Difference between time to next thoracentesis scheduled by the pulmonologist and patient respectively versus time to patient-reported need for thoracentesis [At the day of the next thoracentesis or 2 months after the first study-thoracentesis, whichever comes first.]

      Measured in days. The patients and pulmonologists scheduling is recorded on a questionnaire at the day of first thoracentesis, after the procedure

    Secondary Outcome Measures

    1. Patients experienced well being [At day 1 immediately prior to and immediately after thoracentesis]

      Symptoms measured by ESAS (Edmonton Symptom Assessment System, contains visual analogue scales measuring tiredness, pain, drowsiness, nausea, appetite, dyspnea, depression, anxiety, and general well being, scale 0-10, 0 being no symptoms, 10 being the worse symptoms)

    2. Patients perception of dyspnea [At day 1 immediately prior to and immediately after thoracentesis.]

      Symptoms measured by MBS (Modified Borg Scale, scale1-5, 1 being no dyspnea, 5 being the worse dyspnea)

    3. Patients perception of dyspnea [At day 1 immediately prior to and immediately after thoracentesis.]

      Symptoms measured by MRC (Medical Research Council Dyspnoea Scale, scale1-5, 1 being the least dyspnea, 5 being the worse dyspnea)

    4. Patient experienced dyspnea until next thoracentesis [At the day of the next thoracentesis or 2 months after the first study-thoracentesis, whichever comes first.]

      Measured in a daily diary completed at the same time slot every day by MBS (Modified Borg Scale, scale1-5, 1 being no dyspnea, 5 being the worse dyspnea)

    5. Patient experienced dyspnea until next thoracentesis [At the day of the next thoracentesis or 2 months after the first study-thoracentesis, whichever comes first.]

      Measured in a daily diary completed at the same time slot every day by Measured in a daily diary completed at the same time slot every day by MRC (Medical Research Council Dyspnoea Scale, scale1-5, 1 being the least dyspnea, 5 being the worse dyspnea)

    6. Patient experienced well being until next thoracentesis [At the day of the next thoracentesis or 2 months after the first study-thoracentesis, whichever comes first.]

      Measured in a daily diary completed at the same time slot every day by ESAS Symptoms measured by ESAS (Edmonton Symptom Assessment System, contains visual analogue scales measuring tiredness, pain, drowsiness, nausea, appetite, dyspnea, depression, anxiety, and general well being, scale 0-10, 0 being no symptoms, 10 being the worse symptoms)

    7. Fluid removed at the first study-thoracentesis [At day 1, immediately after end of procedure]

      measured in mL.

    8. Fluid removed at the second study-thoracentesis [At the day of the the second thoracentesis, immediately after end procedure]

      measured in mL.

    9. Correlation between amount of pleural fluid removed at the first study-thoracentesis (outcome 6) and symptoms (well being and dyspnea, outcome 4 and 5) until next thoracentesis. [At the day of the next thoracentesis or 2 months after the first study-thoracentesis, whichever comes first.]

      amount of fluid measured in mL.

    10. Correlation between patient's symptoms (well being and dyspnea, outcome 4, 5and 6) and time to next thoracentesis [At the day of the next thoracentesis or 2 months after the first study-thoracentesis, whichever comes first.]

      Time measured in days

    11. Correlation between time in between thoracentesis and amount of fluid drained at the following thoracentesis [thoracentesis or 2 months after the first study-thoracentesis, whichever comes first.]

      Time measured in days and amount of fluid measured in mL

    12. Correlation between well being and dyspnea (outcome 2, 3 and 4) and findings on lung ultrasound before and after completed thoracentesis [At day 1 immediately after ended procedure]

      Diaphragmatic movement (measured by M-mode and "The Area method", diaphragmatic shape (convex, flat, concave) and Septae-score)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age ≥ 18 years.

    • Unilateral pleural effusion.

    • A minimum of two thoracentesis prior to inclusion.

    • Patients must be able to give informed consent.

    Exclusion Criteria:
    • Bilateral pleural effusions.

    • Inability to understand written or spoken Danish.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Næstved Sygehus, department of pulmonary medicine Næstved Region Sjælland Denmark 4700
    2 Zealand University Hospital, Roskilde Roskilde Zealand Denmark 4000

    Sponsors and Collaborators

    • Naestved Hospital

    Investigators

    • Principal Investigator: Uffe Bødtger, MD, PhD, Department of Pulmonary Medicin, Næstved Sygehus

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Naestved Hospital
    ClinicalTrials.gov Identifier:
    NCT04236934
    Other Study ID Numbers:
    • 19-000067
    First Posted:
    Jan 22, 2020
    Last Update Posted:
    May 11, 2022
    Last Verified:
    May 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 11, 2022